ATE270115T1 - Behandlung einer intrazelluläre infektion - Google Patents

Behandlung einer intrazelluläre infektion

Info

Publication number
ATE270115T1
ATE270115T1 AT00919042T AT00919042T ATE270115T1 AT E270115 T1 ATE270115 T1 AT E270115T1 AT 00919042 T AT00919042 T AT 00919042T AT 00919042 T AT00919042 T AT 00919042T AT E270115 T1 ATE270115 T1 AT E270115T1
Authority
AT
Austria
Prior art keywords
agent
target cell
phage
treatment
combating
Prior art date
Application number
AT00919042T
Other languages
English (en)
Inventor
Vladimir Artymovich Pasechnik
Allen Douglas Glen Roberts
Richard James Sharp
Original Assignee
Health Prot Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Prot Agency filed Critical Health Prot Agency
Application granted granted Critical
Publication of ATE270115T1 publication Critical patent/ATE270115T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT00919042T 1999-04-09 2000-04-10 Behandlung einer intrazelluläre infektion ATE270115T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9908195.2A GB9908195D0 (en) 1999-04-09 1999-04-09 Treatment of intracellular infection
PCT/GB2000/001350 WO2000061190A2 (en) 1999-04-09 2000-04-10 Treatment of intracellular infection

Publications (1)

Publication Number Publication Date
ATE270115T1 true ATE270115T1 (de) 2004-07-15

Family

ID=10851274

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00919042T ATE270115T1 (de) 1999-04-09 2000-04-10 Behandlung einer intrazelluläre infektion

Country Status (12)

Country Link
US (1) US6660264B1 (de)
EP (1) EP1169063B1 (de)
JP (1) JP2002541217A (de)
AT (1) ATE270115T1 (de)
AU (1) AU772115B2 (de)
CA (1) CA2372078A1 (de)
DE (1) DE60011880T2 (de)
DK (1) DK1169063T3 (de)
ES (1) ES2220451T3 (de)
GB (1) GB9908195D0 (de)
PT (1) PT1169063E (de)
WO (1) WO2000061190A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002221713A1 (en) * 2000-10-25 2002-05-06 Intercell Biomedizinische Forschulungs- Und Entwicklungs Ag Modified phage, comprising a non-lytic modification and expressing a kil-gene
JP2004537515A (ja) * 2001-05-15 2004-12-16 フォーク ファーマシューティカルス，インク． ウィルス感染症治療用薬物のターゲッティング送達
GB0115385D0 (en) * 2001-06-22 2001-08-15 Regma Biotechnologies Ltd Novel preparation
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation
CA2475247C (en) * 2002-02-07 2015-08-04 Massachusetts Institute Of Technology Anti-pathogen treatments
GB0205786D0 (en) * 2002-03-12 2002-04-24 Regma Bio Technologies Ltd Novel Composition
GB0209680D0 (en) * 2002-04-27 2002-06-05 Univ Strathclyde Immobilisation and stabilisation of bacteriophage
DE10235967B4 (de) * 2002-08-06 2005-09-08 Bayer Healthcare Ag Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung
WO2004087924A2 (en) * 2003-03-31 2004-10-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for delivery of substances to intracellular microorganisms
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
WO2005080410A1 (en) * 2004-02-20 2005-09-01 Genesis Research And Development Corporation Limited Targeted delivery of rna interference molecules for the treatment of ige-mediated disorders
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
ES2348343T3 (es) * 2006-12-12 2010-12-03 Morphosys Ag Internalización.
US8619257B2 (en) * 2007-12-13 2013-12-31 Kimberley-Clark Worldwide, Inc. Recombinant bacteriophage for detection of nosocomial infection
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
WO2021178968A1 (en) * 2020-03-06 2021-09-10 Endolytix Technology, Inc. Compositions and methods for the treatment of intracellular bacterial infections
WO2025018388A1 (ja) * 2023-07-20 2025-01-23 学校法人自治医科大学 抗菌カプシド、治療用組成物、殺菌剤、細菌除去方法、殺菌方法、動物治療方法、遺伝子導入方法、細菌機能追加方法、抗菌カプシドの製造方法、抗菌カプシドの標識方法、及び抗菌カプシドの細胞内送達方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB829266A (en) 1957-03-20 1960-03-02 Biogena A method of manufacturing bacteriophages in solid dry form
EP0436597B1 (de) 1988-09-02 1997-04-02 Protein Engineering Corporation Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
IL93982A0 (en) 1989-04-03 1991-01-31 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
EP0532525B1 (de) 1990-05-18 1995-08-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue protein-polykation-konjugate
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1992006191A1 (en) 1990-09-28 1992-04-16 Protein Engineering Corporation Proteinaceous anti-dental plaque agents
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
EP1820858B1 (de) 1991-03-01 2009-08-12 Dyax Corporation Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU1581692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Inhibitors of human neutrophil elastase and human cathepsin g
DE4110409C2 (de) 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
DE4115038A1 (de) 1991-05-08 1992-11-12 Genentech Inc Neue konjugate, bestehend aus einem glykoprotein und einer nukleinsaeure-bindenden substanz
WO1993000103A1 (en) 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5922859A (en) 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
CA2159716A1 (en) 1993-04-27 1994-11-10 Symbio Tech, Inc. Method of detecting compounds utilizing chemically modified lambdoid bacteriophage
DE4335025A1 (de) 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
WO1995027043A1 (en) 1994-04-05 1995-10-12 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
MX9605941A (es) 1994-05-30 1997-12-31 Boehringer Ingelheim Int Procedimiento para introducir material extraño en celulas eucarioticas superiores.
DE4418965A1 (de) 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
GB9412844D0 (en) 1994-06-27 1994-08-17 Medical Res Council Improvements in or relating to therapeutic methods
US5736388A (en) 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
WO1997023608A1 (en) 1995-12-22 1997-07-03 Chiron Corporation Compositions and methods for targeting gene delivery vehicles using covalently bound targeting elements
SE506771C2 (sv) * 1996-02-06 1998-02-09 Gotpat 105 Ab Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
CA2251724A1 (en) 1996-04-15 1997-10-23 Paul Averback Compositions containing bacteriophages and methods of using bacteriophages to treat infections
WO1998005344A1 (en) 1996-08-05 1998-02-12 Brigham And Women's Hospital, Inc. Bacteriophage-mediated gene therapy
EP1009819A1 (de) 1997-08-29 2000-06-21 Selective Genetics, Inc. Verfahren zur selektion von einfürungsliganden für die abgabe von genen mittels phagendisplay
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
DE19909770A1 (de) * 1999-03-05 2000-09-07 Werner Lubitz Bakterienghosts als Träger- und Targetingvehikel

Also Published As

Publication number Publication date
PT1169063E (pt) 2004-10-29
DK1169063T3 (da) 2004-11-01
EP1169063A2 (de) 2002-01-09
AU772115B2 (en) 2004-04-08
CA2372078A1 (en) 2000-10-19
EP1169063B1 (de) 2004-06-30
WO2000061190A3 (en) 2001-03-01
US6660264B1 (en) 2003-12-09
ES2220451T3 (es) 2004-12-16
DE60011880T2 (de) 2005-08-25
GB9908195D0 (en) 1999-06-02
WO2000061190A2 (en) 2000-10-19
JP2002541217A (ja) 2002-12-03
AU3979800A (en) 2000-11-14
DE60011880D1 (de) 2004-08-05

Similar Documents

Publication Publication Date Title
ATE270115T1 (de) Behandlung einer intrazelluläre infektion
YU4602A (sh) Farmaceutske formulacije zaštićene od dejstva mikroorganizama
PL341364A1 (en) 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents
BR9909994A (pt) Quinolinas usadas como inibidores de mrs e bactericidas
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
GEP20053429B (en) 3-Aminoquinazolin-2,4-Dione, Pharmaceutical Composition Containing Them and Use Thereof as Antibacterial Agents
EP1024145A3 (de) Neue Azalide und Verfahren zu deren Herstellung
MY125356A (en) Moxifloxacin/sodium chloride formulation
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
SE9900961D0 (sv) Novel compounds
AU2001266575A1 (en) Chemical compounds
SE9903997D0 (sv) New compounds
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
AU2002213419A1 (en) Condensed pyridoindole derivatives
WO2021178818A3 (en) Therapeutic agents and conjugates thereof
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
GEP20012423B (en) Composition for Organ Cryopreservation and Treatment of Viral and Bacterial Infections
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
WO2002049633A3 (en) Use of amidoamines to treat or prevent acanthamoeba and fungal infections
DE60005530D1 (de) Antiseptische zusammensetzungen
NZ504614A (en) Echinocandin derivatives and application as anti-fungal agents
SE9800905D0 (sv) New therapy in glomerulonephritis
AR023282A1 (es) Derivados de higromicina
WO2000041473A3 (de) Verwendung von 3-isoxazolidinonen und hydroxylaminsäuren zur behandlung von infektionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1169063

Country of ref document: EP

REN Ceased due to non-payment of the annual fee